Recombinant Spike Protein from Novel Coronavirus (SARS-CoV-2/Wuhan/2019), Trimeric

IT-002-032p: Recombinant Spike Protein from Novel Coronavirus (SARS-CoV-2/Wuhan/2019), Trimeric

The novel coronavirus pandemic, COVID-19, has catalyzed the development of vaccines and antiviral drugs across the biotech industry, both by pharmaceutical companies and research organizations. Based on scientific evidence presented in the literature, it appears that the inhibition of the binding of the Spike glycoprotein from the coronavirus, SARS-Cov-2, to its receptor, angiotensin-converting enzyme 2 (ACE2), would be the key for developing biologics targeting virus entry into the host cells. Molecules with such ACE Inhibition (ACEI) activity have a great potential for further evaluation for treatment or prophylactic applications. Based on the experience and analysis of our scientists and academic consultants, we believe that the entry event of the novel coronavirus seems to combine the smart features of the Human Immunodeficiency Virus (HIV) glycan shield and the Respiratory Syncytial Virus (RSV) Pre-fusogenic F protein trimer to evade the host immune recognition and subsequent immune attack. Therefore, we acknowledge the urgent need for high-quality reagents of the SARS-Cov-2 Spike protein which can be a great tool to aid the discovery of neutralizing antibodies with prophylactic and therapeutic potentials, and the development of effective vaccines. Immune Tech has produced a trimeric version of the Spike protein from SARS-Cov-2 in HEK293 mammalian cells, SKU: IT-002-032p. The purified protein shows a distinct band with molecular weight of about 180KDa, suggesting heavy glycosylation for the protein of 1214 amino acid residues in length (Left Panel). Furthermore, data from Gel Filtration Chromatography demonstrate that the purified proteins have a retention time of about 50 minutes, similar to that of thyroglobulin (MW=670KDa), indicating that the vast majority of expressed Spike proteins from SARS-Cov-2 is in trimeric state. Taken together, this data present sufficient evidence that the Spike protein from SARS-Cov-2 we have produced (SKU: IT-002-032p) may closely resemble the native S protein on the virus particle thus may be a useful tool for the development of therapeutic antibodies and vaccines against COVID-19 pandemic.At Immune Tech, it is our mission to engage our fullest capacity, knowledge base, and enthusiasm in our effort to help combating the novel coronavirus pandemic. We look forward to your comments, suggestions, and collaboration.


Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

 See all authors and affiliations

Science  13 Mar 2020:
Vol. 367, Issue 6483, pp. 1260-1263
DOI: 10.1126/science.abb2507